Author:
Outteryck Olivier,Ongagna J.-C.,Zéphir H.,Fleury M.-C.,Lacour A.,Blanc F.,Vermersch P.,Sèze J.
Publisher
Springer Science and Business Media LLC
Subject
Clinical Neurology,Neurology
Reference14 articles.
1. Agence Française de Sécurité Sanitaire des Produits de Santé. Bon usage; Mise au point: Utilisation de la spécialité TYSABRI® 300 mg (natalizumab) dans le traitement de la sclérose en plaques [PDF in French]. http://www.afssaps.fr/content/download/6205/60160/version/4/file/mise_au_tysabri.pdf . Accessed 22 Mar 2009
2. Biogen Idec, Inc. TYSABRI update. http://www.biogenidec.com/site/tysabri-information-center.html . Accessed 26 Mar 2009
3. Calabresi PA, Giovannoni G, Confavreux C, Galetta SL, Havrdova E, Hutchinson M, Kappos L, Miller DH, O’Connor PW, Phillips JT, Polman CH, Radue EW, Rudick RA, Stuart WH, Lublin FD, Wajgt A, Weinstock-Guttman B, Wynn DR, Lynn F, Panzara MA (2007) The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. Neurology 69:1391–1403
4. Confavreux C, Vukusic S (2006) Natural history of multiple sclerosis: a unifying concept. Brain 129:606–616
5. European Medicines Agency. TYSABRI European public assessment report: scientific discussion. http://www.emea.europa.eu/humandocs/PDFs/EPAR/tysabri/H-603-en6.pdf . Accessed 31 Mar 2009
Cited by
37 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献